Celltrion Pharmaceuticalannounced on the 14th through its management performance disclosure that its sales in the third quarter increased by 37.2% compared to the same period last year, reaching approximately KRW 128.1 billion, breaking its record-high quarterly performance.
During the same period, operating profit increased by 108.3% to approximately KRW 13.6 billion, recording an operating profit ratio of 10.7%. The cumulative performance for the third quarter was calculated to be approximately KRW 342.3 billion in sales and KRW 26.8 billion in operating profit. Celltrion Pharmaceuticals, which drove sales growth through the promotion of major products and the effects of new products, focused on improving operating profits by reducing sales commissions, despite expanding manpower and increasing research and development expenses.
In the chemical business division, the main product, soy sauce solvent ‘Godex‘, recorded sales of approximately KRW 18.2 billion, and the hypertension treatment drug ‘Dillatren Tablet’, which began full-scale sales in the second quarter of last year, recorded sales of approximately KRW 12.8 billion, helping growth.
In the biosimilar business division, the number of patients prescribed ‘Remsima SC‘, an autoimmune disease treatment that changed the intravenous (IV) formulation to subcutaneous injection (SC), grew by about 60% compared to the same period last year. In addition, while breast cancer and stomach cancer treatment ‘Herzuma’ and blood cancer treatment ‘Truxima’ are doing well, sales of autoimmune disease treatment ‘Uplyma‘ and anticancer drug ‘Begzelma’ launched last year are becoming visible, resulting in quarterly sales of about 217.7%. It recorded billions of won.
Celltrion Pharmaceutical will continue to expand sales by establishing new products in the market and increasing production, while securing differentiated competitiveness through investment in research and development (R&D) to spur growth with the goal of becoming one of the top five pharmaceutical companies in Korea by 2030. The plan is to do so.
First of all, Celltrion Pharmaceuticals is focusing on marketing as three new biosimilar products successfully entered the market in September, including autoimmune disease treatment ‘Stechima’, eye disease treatment ‘Idengelt’, and allergic asthma treatment ‘Omriclo’. The plan is to strengthen and focus on increasing performance.
We plan to work with Kukje Pharmaceutical and Daewoong Pharmaceutical, which have signed a joint sales business agreement, to ensure that high-quality treatments are stably supplied to the market.
In addition, we plan to accelerate the strengthening of profitability as we have completed the internalization of production of major acquired products such as diabetes treatment ‘Nesina’ and hypertension treatment ‘Edalbi’ and production and supply are currently progressing smoothly.
The PFS (Prefilled Syringe) production facility at the Cheongju plant, which has entered full-scale commercial production, has completed major GMP (Good Manufacturing Practices) certifications from major global regulatory agencies and is reaching full capacity due to increased production. As it is being operated as a production system, it is expected to establish itself as a sustainable growth engine. Currently, Celltrion is producing major products such as ‘Zympentra’ and ‘Uplyma’ sold in earnest, recording a sales growth of 577% compared to the same period last year.
In research and development (R&D), together with Celltrion, we are focusing on the development of new improved combination drugs that increase the convenience of taking medication in the fields of diabetes and hypertension treatments. We are preparing for the domestic approval process for a combination of three drugs for hypertension and hyperlipidemia, so growth is expected through expansion of follow-up products. It is becoming.
An official from Celltrion Pharmaceutical said, “This third quarter, the even growth of our flagship products led to solid sales performance,” and added, “We will achieve our Vision 2030 goal by consolidating the substance of our major items while accelerating new business and R&D innovation.”
